CN102892432A - 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 - Google Patents

用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 Download PDF

Info

Publication number
CN102892432A
CN102892432A CN201180024138XA CN201180024138A CN102892432A CN 102892432 A CN102892432 A CN 102892432A CN 201180024138X A CN201180024138X A CN 201180024138XA CN 201180024138 A CN201180024138 A CN 201180024138A CN 102892432 A CN102892432 A CN 102892432A
Authority
CN
China
Prior art keywords
antibody
neovascularization
antibody according
disease
conservative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180024138XA
Other languages
English (en)
Chinese (zh)
Inventor
P·勒布泰耶
A·邦叙桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Mablife SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Mablife SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Mablife SAS filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN201710912201.2A priority Critical patent/CN107648605A/zh
Publication of CN102892432A publication Critical patent/CN102892432A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180024138XA 2010-05-28 2011-05-27 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 Pending CN102892432A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710912201.2A CN107648605A (zh) 2010-05-28 2011-05-27 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34927110P 2010-05-28 2010-05-28
US61/349,271 2010-05-28
PCT/EP2011/058777 WO2011147984A1 (en) 2010-05-28 2011-05-27 Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710912201.2A Division CN107648605A (zh) 2010-05-28 2011-05-27 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体

Publications (1)

Publication Number Publication Date
CN102892432A true CN102892432A (zh) 2013-01-23

Family

ID=44276158

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180024138XA Pending CN102892432A (zh) 2010-05-28 2011-05-27 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体
CN201710912201.2A Pending CN107648605A (zh) 2010-05-28 2011-05-27 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710912201.2A Pending CN107648605A (zh) 2010-05-28 2011-05-27 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体

Country Status (11)

Country Link
US (2) US9045544B2 (enExample)
EP (1) EP2575881B1 (enExample)
JP (1) JP5990511B2 (enExample)
KR (1) KR101847572B1 (enExample)
CN (2) CN102892432A (enExample)
BR (1) BR112012030318A2 (enExample)
CA (1) CA2796312C (enExample)
DK (1) DK2575881T3 (enExample)
ES (1) ES2606627T3 (enExample)
PL (1) PL2575881T3 (enExample)
WO (1) WO2011147984A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121508A (zh) * 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
CN110381999A (zh) * 2017-01-06 2019-10-25 埃尔萨里斯生物技术公司 结合人cd160的化合物及其用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3145532A4 (en) * 2014-05-02 2018-02-21 Mayo Foundation for Medical Education and Research Individualized treatment of eye disease
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3675889A4 (en) * 2017-08-31 2021-05-12 Singapore Health Services PTE Ltd ANGIO -3 FOR THE TREATMENT OF ANGIOGENIC RETINAL DISEASES
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021138409A2 (en) * 2019-12-31 2021-07-08 Medstar Health, Inc. Anti-cd160 binding molecules for treating diseases
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
KR20250068626A (ko) 2022-09-15 2025-05-16 아비디큐어 아이피 비.브이. Nk 세포 자극을 위한 다중특이적 항원 결합 단백질 및 이의 용도
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015886A1 (en) * 2004-08-09 2006-02-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2
EP2186529A2 (en) * 2007-08-07 2010-05-19 Asociación Civil De Estudios Superiores Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
DE69327229T2 (de) 1992-12-11 2000-03-30 The Dow Chemical Co., Midland Multivalente einkettige Antikörper
WO1998021240A1 (en) 1996-11-12 1998-05-22 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2794977B1 (fr) * 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
EP1981520A2 (en) * 2006-01-30 2008-10-22 (OSI) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015886A1 (en) * 2004-08-09 2006-02-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2
EP2186529A2 (en) * 2007-08-07 2010-05-19 Asociación Civil De Estudios Superiores Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PIERRE FONS等: "Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells", 《BLOOD》, vol. 108, no. 8, 29 June 2006 (2006-06-29), pages 2608 - 2615, XP002530233, DOI: doi:10.1182/blood-2005-12-019919 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121508A (zh) * 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
CN110381999A (zh) * 2017-01-06 2019-10-25 埃尔萨里斯生物技术公司 结合人cd160的化合物及其用途
CN110381999B (zh) * 2017-01-06 2023-12-01 埃尔萨里斯生物技术公司 结合人cd160的化合物及其用途

Also Published As

Publication number Publication date
CA2796312A1 (en) 2011-12-01
JP2013528607A (ja) 2013-07-11
CA2796312C (en) 2020-11-03
KR101847572B1 (ko) 2018-05-24
US20150344572A1 (en) 2015-12-03
DK2575881T3 (en) 2017-01-09
US20130122006A1 (en) 2013-05-16
ES2606627T8 (es) 2017-06-09
WO2011147984A1 (en) 2011-12-01
KR20130086548A (ko) 2013-08-02
PL2575881T3 (pl) 2018-06-29
US9045544B2 (en) 2015-06-02
BR112012030318A2 (pt) 2017-06-20
JP5990511B2 (ja) 2016-09-14
ES2606627T3 (es) 2017-03-24
CN107648605A (zh) 2018-02-02
US10208124B2 (en) 2019-02-19
EP2575881B1 (en) 2016-09-14
EP2575881A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
CN102892432A (zh) 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体
Julien et al. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes
Zhang et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration
US20170196988A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
TW201522378A (zh) 用於治療人類癌症的特異性抗ｃｄ３８抗體
KR20180134367A (ko) 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
TWI844571B (zh) 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EA037551B1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
AU2016241499A1 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
JP4857259B2 (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
CN114728061A (zh) 治疗糖尿病性视网膜病变的方法和组合物
US20110110932A1 (en) Combination treatment for ocular diseases
US9463217B1 (en) Methods and pharmaceutical compositions for treatment of retinal occlusion
JP7189878B2 (ja) ヒトｃｄ１６０を結合する結合物及びその使用
WO2022201084A1 (en) Methods for treating ocular diseases
CN113645994A (zh) 使用色素上皮衍生因子(pedf)治疗疾病的方法
Taubitz et al. Effects of intravitreally injected Fc fragment on rat eyes
RU2843013C1 (ru) Способы и композиции для лечения диабетической ретинопатии
JP2007510738A (ja) ＣＤ１１ｄ（α−ｄ）インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法
EP3538553A1 (en) Anti-secretogranin iii (scg3) antibodies and uses thereof
TW202532435A (zh) 治療新生血管性眼疾之方法
WO2025081130A1 (en) Use of anti-asc antibody in the treating of ocular disorders
WO2023160517A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
TW202438525A (zh) Lair-1促效性抗體及其使用方法
EP4615871A1 (en) Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130123